Guillain-Barre’ Syndrome

Lakshmi K, Dinesh K, Bindu D, Sharanya K

Department of Microbiology, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research (BIHER), Chennai, Tamil Nadu, India.

Corresponding author: bindu.d@bharathuniv.ac.in
**ABSTRACT**

Guillain-Barre’ syndrome (GBS) is characterized by rapidly evolving symmetrical limb weakness, loss of tendon reflexes, absent or mild sensory signs, and variable autonomic dysfunction. It occurs most commonly after a respiratory tract or a gastrointestinal infection. *Campylobacter jejune* and cytomegalovirus (CMV) constitute the most frequent bacterial and viral triggers. Epstein-Barr virus (EBV), *Mycoplasma pneumonia*, and human immunodeficiency virus (HIV) have also been associated with GBS whereas parvovirus B19 (B19V) is not usually cited as a cause of GBS. We report a case of GBS in a chronically HIV-infected patient in association with a primary B19V infection.

**Key words:** Guillain-Barre’ syndrome, human immunodeficiency virus and B19V infection.
Case Presentation

A 63-year-old man was admitted because of severe weakness of his inferior limbs that had worsened within a week. Ten months earlier, he had been diagnosed with advanced HIV-1 infection (relapsing bacterial pneumonia, oropharyngeal candidiasis, weight loss, CD4 lymphocytes 75 cells/mm³, viral load 433,413 copies/mL). Antiretroviral therapy (ART) with tenofovir, emtricitabine, and boosted darunavir had been started at this time and regularly taken since then. Three months before admission, he had suffered from vertebral fractures due to osteoporosis and had been treated with bisphosphonates, calcium, and vitamin D₃. One month before admission his CD4 count was 274 cells/mm³ (20% of total lymphocytes) and his HIV viral load was <20 copies/mill at admission, he had been on dexamethasone 4 mg/day for 5 weeks, administered by his family doctor because of persisting vertebral pain. A diffuse flaccid Paraparesis was present with loss of tendon reflexes, multimodal distal sensory loss, and proprioceptor-tie ataxia. A newly appeared blood pancytopenia was present (leucocytes 1100 cells/mm³, hemoglobin 95 g/L, thrombocytes 25 cells/mm³).

Creatinine and liver function tests were in the normal range. The CD4 count was 26 cells/mm³ (16% of total lymphocytes) and the HIV viral load 44 copies/mill No thoracic or abdominal lesions were detected by CT scan. Electroneuromyography (ENMG) was highly suggestive of demyelinating polyradiculoneuropathy with prolonged distal motor latencies (>9 ms), decreased amplitudes of compound muscle action potential, slow nerve conduction velocities (30 m/s), and increased F-waves latencies (>63 ms), without acute denervation. No medullar lesion suggestive of any viral infection was seen by MRI of the lumbar and thoracic spine. The CSF examination showed elevated proteins (600 mg/L) without leucocytes, erythrocytes, or atypical cells. Serum IgG, without IgM, were present against CMV, varicella zoster virus (VZV), and EBV, the latter with anti-EBNA IgG. No IgG or IgM against B19V were found. Blood PCRs were positive for B19V (520 × 10⁹ copies/mL), EBV (14.4 × 10³ copies/mL), and CMV (4.3 × 10³ copies/mL). CSF PCRs were positive for B19V (290 × 10³ copies/mL) and EBV (1.2 × 10³ copies/mL). They were negative for HIV, CMV, and VZV.

After the interruption of corticosteroids and a five-day course of intravenous immunoglobulins (IVIG) 0.4 g/kg/day, the neurological symptoms regressed and the patient could leave the hospital. Eight days after the end of the treat-ment, the pancytopenia had disappeared (leucocytes 7500 cells/mm³, hemoglobin 102 g/L, and thrombocytes 174 cells/mm³), serum IgG and IgM against B19V were present, and the B19V viral load was 3 log lower (537 × 10³/mL). It was 190 × 10³/mL a month later and 27 × 10³/mL 2 months later.

Six weeks after onset of the neurologic disease, a second ENMG showed a reduction of the above-mentioned abnormalities. Three months later the patient was readmitted for fever.
without neurological symptoms. The B19V viremia was $3.9 \times 10^3$ copies/mL and the EBV viremia $18.9 \times 10^3$ copies/mL. No CMV DNA was detected by PCR. Despite extensive workout the fever remained of unknown origin until his death a month later. The autopsy revealed a peripheral T-cell lymphoma with EBV-infected lymphoblasts in the lymph nodes, liver, and bone marrow.

**Result and Discussion**

According to Singer et al., HIV-associated neurological syndromes can be classified as primary HIV neurological disease, treatment-related neurological disease, and secondary or opportunistic neurological disease. Because of this patient’s low serum HIV viral load, his undetectable CSF HIV level, and his predominantly motor involvement, it is unlikely that he suffered from a primary HIV polyneuropathy. Since his antiretroviral treatment did not include drugs that have usually been associated with neurological toxicity and since his symptoms regressed despite their continuation, an ART-associated neuropathy is also improbable. Various etiologies are cited for secondary neurological diseases occurring in HIV-infected patients. They can be related to tumors or opportunistic infections. Paraneoplastic neuropathies are usually predominantly sensory and may appear with lymphomas. Although this patient died of a T-cell lymphoma 4 months after he presented with GBS, we do not believe that polyneuropathy and pancytopenia were caused by a still undetected lymphoma.

Indeed, both neurological and hematological abnormalities developed on dexamethasone, which should have had a positive effect on a beginning lymphoma, and they regressed in parallel with the B19V viremia after the interruption of corticosteroids. CMV is the most common viral trigger of GBS but was not found by PCR in this patient’s CSF. EBV, well known for causing lymphoproliferative diseases in immunodeficient hosts [6], has been reported as a potential cause of GBS, mostly in primary infection and less frequently in chronic infection. This patient was chronically infected by EBV with persistent viremia and presence of viral DNA in his CSF. EBV might thus have participated in his neurological disease, but, since the regression of the symptoms was linked with a decrease in B19V DNA titers whereas EBV DNA titers remained stable through the clinical history, we do not think that EBV played a major role in his polyneuropathy. B19V infection is common during childhood but occurs also in adults. Serum IgG against B19V are detectable in approximately 50% of 15-year-old children and 80% of elderly people [8]. B19V has a wide variety of clinical manifestations, *erythema infectiosum* (the 5th disease), arthritis, and transient aplastic crisis being the most frequent.
In immunodeficient hosts, persistent B19V viremia typically causes pure red cell aplasia and chronic anemia, but it has also been associated with varying degrees of neutropenia or thrombocytopenia. More rarely, neurologic disease, myocarditis, kidney disease, hepatitis, and vasculitis have been attributed to B19V. Most of them were children with central nervous system (CNS) manifestations such as seizures or meningitis (median age: 8 years). Peripheral nervous system (PNS) manifestations were reported in 19 patients with a median age of 29.5 years (range 16 months–49 years). These PNS manifestations included brachial plexus neuropathy (8 cases), carpal tunnel syndrome (6 cases), cranial and peripheral neuropathies (4 cases), and a single case of GBS in a 4-year-old boy. To our knowledge, 3 other cases of GBS or GBS variant have been reported in association with B19V infection, in 2 adults, and 1 child. None of them had altered immunity (Dalugama and Gawarammana, 2018).

**Conclusion**

Our patient presented with an acute demyelinating polyneuropathy. Major biological features were pancytopenia, albuminocytologic dissociation, high levels of B19V DNA in serum and CSF during the acute phase in the absence of B19V IgG and IgM, and decrease of the viral load after a 5-day course of IVIG concomitant with clinical improvement. As most of the immunodeficient patients in the Douvoyiannis’ review, our patient’s neurological disease was not associated with other symptoms of B19V infection such as flu-like syndrome, rash, or arthritis. This could have been due to HIV infection and corticosteroids, both impairing his inflammatory response. In conclusion, this case illustrates the multiple factors that can contribute to peripheral nervous system manifestations in immunodeficient patients. It emphasizes the importance of looking for infection with neurotropic viruses by PCR in such situations and adds to the current evidence (Singh et al., 2001; Alghamdi et al., 2013; Avasthi et al., 2013).

**Author contribution:** Lakshmi K, Dinesh K, Bindu D, Sharanya K encouraged and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

**Acknowledgement:** Nil

**Conflict of interest:** Nil

**Study significance:** Epstein-Barr virus (EBV), Mycoplasma pneumonia, and human
immunodeficiency virus (HIV) have also been associated with GBS whereas parvovirus B19 (B19V) is not usually cited as a cause of GBS. We report a case of GBS in a chronically HIV-infected patient in association with a primary B19V infection.

REFERENCE


